AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!

ÈÕ±¾ÕZ
ÐÂÎÅÖÐÐÄ

6/24

2024

AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!×ÔÖ÷¿ª·¢µÄ´´ÐÂÒ©¹ÈÃÀÌæÄᣨMETÒÖÖƼÁ£©³É¹¦ÔÚÈÕ±¾»ñÅúÉÏÊÐ

º£ºÍÒ©Îï½ñÈÕÐû²¼£¬¹«Ë¾×ÔÖ÷¿ª·¢²¢ÓµÓÐÍêȫ֪ʶ²úȨµÄ¡¢ÉϺ£Ò©ÎïËù·¢ÏֵĴ´ÐÂÒ©ÎïMETÒÖÖƼÁ¹ÈÃÀÌæÄáƬÒÑ»ñµÃÈÕ±¾ºñÉúÀͶ¯Ê¡Åú×¼ÉÏÊС£±¾´ÎÉ걨ÉÏÊеÄÊÊӦ֢Ϊ£ºÓÃÓÚÖÎÁƾßÓÐMET 14ÍâÏÔ×ÓÌø±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔ·ÇСϸ°û·Î°©¡£

 

±¾´ÎÊÊÓ¦Ö¢µÄÉÏÊÐÐí¿ÉÉêÇëÖ÷Òª»ùÓÚSCC244-108¹Ø¼üIIÆÚÑо¿£¨GLORYÑо¿£¬NCT04270591£©µÄÓÐЧÐԺͰ²È«ÐÔÊý¾Ý¡£¸ÃÑо¿ÊÇÒ»Ïî¶à¹ú¡¢¶àÖÐÐĵĿª·Å¡¢µ¥±ÛÁÙ´²ÊÔÑ飬ּÔÚÆÀ¹À¹ÈÃÀÌæÄáƬÓÃÓÚ¾ßÓÐMET 14 ÍâÏÔ×ÓÌø±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔ·ÇСϸ°û·Î°©ÈËȺµÄÁÆЧºÍ°²È«ÐÔ¡£¸ÃÊÊÓ¦Ö¢ÒÑÓÚ2023Äê3ÔÂ7ÈÕ»ñµÃÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÉÏÊС£¸ÃÑо¿µÄÈ«ÇòÖ÷ÒªÑо¿ÕßÊÇÖйúÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôÐØ¿ÆҽԺ½˴½ÌÊÚ¡£

 

½ØÖ¹ÖÁ2022Äê4ÔÂ28ÈÕ£¬GLORYÑо¿ÖУ¬79Àý¾­ÖÐÐÄʵÑéÊÒÈ·ÈÏΪMETex14Ìø±ä»¼Õß12¸öÔÂËæ·ÃÊý¾ÝÏÔʾ£ºÓÉä̬¶ÀÁ¢Ó°ÏñÆÀ¹ÀίԱ»á£¨BIRC£©ÆÀ¹ÀµÄ×ÜÌå¿Í¹Û»º½âÂÊ£¨ORR£©Îª65.8%£¬ÆäÖгõÖλ¼ÕßµÄORRΪ70.5%£¬¾­Öλ¼ÕßµÄORRÒ²´ïµ½60.0%£¬×ÜÌåÈËȺµÄÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©Îª8.5¸öÔ£¬ÆäÖгõÖλ¼Õß´ï11.7¸öÔ£¬¾­Öλ¼ÕßΪ7.6¸öÔ£»×ÜÌåÈËȺµÄÖÐλ×ÜÉú´æÆÚ£¨mOS£©Îª17.3¸öÔ£¬ÆäÖгõÖλ¼ÕßÉÐδ´ïµ½£¬¾­Öλ¼ÕßΪ16.2¸öÔ£¬ÁÆЧÃ÷È·¡£°²È«ÐÔ·½Ã棬ÕûÌ尲ȫÄÍÊÜ£¬³£¼û²»Á¼·´Ó¦°üÀ¨Ë®Öס¢Í·Í´¡¢Ïû»¯µÀÖ¢×´ºÍ¸ÎÔàת°±Ã¸Éý¸ßµÈ£¬¶àΪÇáÖжÈ£¬¾­¶ÔÖ¢ÖÎÁƺó¿É»º½â»ò»Ö¸´£¬ÎÞDZÔڹⶾÐÔ£¬Òàδ¹Û²ìµ½Ïà¹ØµÄ¹ýÃô·´Ó¦£¬Ò©ÎïÏ໥×÷ÓÃÉÙ£¬ºÏ²¢ÓÃÒ©°²È«ÐÔ·çÏսϵ͡£

 
AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!Ê×ϯִÐйٶ­Èðƽ²©Ê¿±íʾ£º
“´Ë´Î¹ÈÃÀÌæÄáƬÔÚÈÕ±¾»ñÅúÉÏÊÐÊǹ«Ë¾ÓÖÒ»ÖØÒªÀï³Ì±®£¬Í¹ÏÔÁ˹«Ë¾ÖÂÁ¦ÓÚ¿ª·¢ºÍÌṩÖ×Áö´´ÐÂÁÆ·¨£¬ÒÔÂú×ãÖйúºÍÈ«Çò»¼ÕßµÄδÂú×ãµÄÒ½ÁÆÐèÇó¡£¹«Ë¾×ñÑ­ “¸ùÖ²Öйú£¬·ÅÑÛÈ«Çò”µÄ¹ú¼Ê»¯Õ½ÂÔ£¬½«¼ÌÐøÈ«Á¦Íƶ¯¹«Ë¾¸ü¶à²úÆ·×ßÏòÊÀ½ç£¬Îª¸ü¶àº£Í⻼ÕßÌṩÀ´×ÔÖйúµÄ¸ßÖÊÁ¿´´ÐÂÒ©Îͬʱ¸ÐлËùÓвÎÓë¹ÈÃÀÌæÄáÁÙ´²Ñо¿µÄÑо¿Õß¡¢»¼Õß¡¢»¼Õß¼ÒÊô¼°ÁÙ´²¹¤×÷ÈËÔ±µÄÐÁÇÚ¸¶³ö£¡”
 
GLORYÑо¿È«ÇòÖ÷ÒªÑо¿ÕßÖйúÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôÐØ¿ÆҽԺ½˴½ÌÊÚ±íʾ£º
“¹ÈÃÀÌæÄáƬÔÚÈÕ±¾µÄ»ñÅú£¬ÊÇÖйú´´ÐÂÒ©×ßÏòÊÀ½çµÄÒ»¸öеÄÀï³Ì±®£¬Ò²Ö¤ÊµÁËÎÒÃÇÖйúÑо¿ÕßÖ÷µ¼µÄ¹ÈÃÀÌæÄáƬGLORYÑо¿µÃµ½Á˹ú¼ÊÈϿɺͿ϶¨¡£ÎÒÃÇÆÚ´ýÄÜÓиü¶àÖйúµÄ´´ÐÂÒ©ÎïÏñ¹ÈÃÀÌæÄáƬһÑù×ß³ö¹úÃÅ£¬Âú×ãÈ«Çò»¼ÕßδÂú×ãµÄÖÎÁÆÐèÇó¡£”
 
¹ØÓÚ·ÇСϸ°û·Î°©£¨NSCLC£©ºÍMET 14ÍâÏÔ×Ó£¨METex14£©Ìø±ä

Ô­·¢ÐԷΰ©ÊÇÈ«Çò·¢²¡ÂʵڶþºÍËÀÍöÂʵÚÒ»µÄ¶ñÐÔÖ×Áö£¬·ÇСϸ°û·Î°©£¨NSCLC£©Ô¼Õ¼ËùÓзΰ©µÄ85£¥1£¬METex14Ìø±äÔÚNSCLCÖеÄ×Ü·¢ÉúÂÊԼΪ3%2¡£ÔÚÖйúNSCLCÈËȺÖÐMETex14Ìø±äµÄ·¢ÉúÂÊÔ¼2.51%3¡£METex14Ìø±äÊÇÔ­·¢Ö°©Çý¶¯»ùÒò£¬Í¨³£²»ÓëEGFR¡¢ KRAS¡¢ ALKµÈ·Î°©ÆäËûÍ»±ä¹²´æ1¡£¶à·¢ÓÚ¸ßÁ仼Õߣ¬ÖÐλÄêÁä72Ëê2¡£METex14Ìø±äԤʾԤºó²î£¬»¯ÁÆÒ©Îï¶þÏßÖÎÁÆÎÞ½øÕ¹Éú´æʱ¼ä£¨PFS£©½öΪ2.9¸öÔ£¬×ÜÉú´æÆÚ£¨OS£©Îª7.9-8.3¸öÔ£¬¿Í¹Û»º½âÂÊ£¨ORR£©Îª8.8%-9.1%2¡£Ð¯´øMETex14Ìø±äµÄNSCLC»¼Õ߶ÔPD-1µ¥¿¹ÖÎÁƲ»Ãô¸Ð£¬ORRΪ16~17%£¬ÖÐλPFSΪ1.9~3.4¸öÔ£¬ÔÚPD-L1ÊÜÌå¸ß±í´ïµÄÖ×Áö»¼ÕßÖУ¬Î´¼û»º½âÂÊÉý¸ß5-6¡£ÔÚÈÕ±¾£¬Ð·¢·Î°©»¼ÕßÈËÊýΪ126,548ÈË/Ä꣬ËÀÍöÈËÊýΪ75,585ÈË/Ä꣨2020£©7¡£NSCLCÔ¼Õ¼ÈÕ±¾·Î°©»¼ÕßµÄ88%£¬³õÕïIVÆÚ»¼ÕßԼΪ30%£¬METex14Ìø±äµÄ·¢ÉúÂÊԼΪ3%2¡£Òò´ËÔÚÈÕ±¾£¬¿ÉÄÜÐèÒª½ÓÊÜÕâÖÖÒ©ÎïÖÎÁƵĻ¼ÕßÈËÊý¹À¼ÆԼΪ1200ÈË/Äê¡£

¹ØÓÚ¹ÈÃÀÌæÄáƬ£¨Ñз¢´úºÅ£ºSCC244£©

¹ÈÃÀÌæÄáƬ£¨Ñз¢´úºÅ£ºSCC244£©ÊÇÒ»¿î¿Ú·þǿЧ¡¢¸ßÑ¡ÔñÐÔС·Ö×ÓMETÒÖÖƼÁ¡£ÁÙ´²Ç°Ñо¿ÏÔʾ¹ÈÃÀÌæÄáƬ¿ÉǿЧºÍÌØÒìÐÔ°ÐÏòÒÖÖÆMET¼¤Ã¸»îÐÔ¡£ÁÙ´²Ñо¿½á¹ûÏÔʾ£¬¹ÈÃÀÌæÄáƬ¾ßÓÐÓÅÁ¼µÄÒ©´ú¶¯Á¦Ñ§ÌØÐÔÒÔ¼°Á¼ºÃµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£¬ÔÚ¾ßÓÐMET¸Ä±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÖÐÏÔʾÁËÃ÷È·ÁÆЧÇÒÄÔתÒÆ»¼ÕßͬÑù»ñÒæ¡£ÓëÒÑÉÏÊÐͬÀà²úÆ·Ïà±È£¬¹ÈÃÀÌæÄáƬÎÈ̬¹ÈŨ¶È¸ü¸ß£¬¿ÉÒÔ³ÖÐøÒÖÖưеã; °ëË¥ÆÚ³¤£¬ÊʺÏÿÈÕÒ»´Î¸øÒ©; ²»ÐèÒª¸ù¾ÝÌåÖص÷Õû¼ÁÁ¿; Ò©ÎïÏ໥×÷ÓÃÉÙ£¬ºÏ²¢ÓÃÒ©°²È«ÐÔ·çÏյ͡£¹ÈÃÀÌæÄáƬ³É¹¦ÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Î²¢»ñµÃÖйúÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÉÏÊÐÓÃÓÚMET 14ÍâÏÔ×ÓÌøԾͻ±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼Õß¡£Í¬Ê±£¬Ò²ÕýÔÚ»ý¼«¿ªÕ¹ÆäËûÁÙ´²Ñо¿£¬±ÈÈçÕë¶ÔMET¹ý±í´ïÇÒÇý¶¯»ùÒòÒõÐÔµÄNSCLC»¼ÕßµÄIIIÆÚÁÙ´²Ñо¿¡£

¹ØÓÚº£ºÍÒ©Îï

º£ºÍÒ©ÎïÊÇÖйúÁìÏȵÄ×ÔÖ÷´´ÐÂÉúÎï¼¼Êõ¹«Ë¾£¬×¨×¢ÓÚ¿¹Ö×Áö´´ÐÂÒ©ÎïµÄ·¢ÏÖ¡¢¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯£¬Ï£ÍûΪȫÇò°©Ö¢»¼Õß´øÀ´¸ü°²È«¡¢¸üÓÐЧµÄÖÎÁÆ·½·¨¡£º£ºÍÒ©Îï¼á³Ö×ß×ÔÖ÷´´ÐµĵÀ·£¬Í¬Ê±ÓµÓÐÒ»Ö§¾ßÓÐÈ«Çò»¯ÊÓÒ°µÄ¿ÆÑк͹ÜÀíÍŶÓ£¬»ý¼«²¼¾Ö´´ÐÂÒ©ÎïµÄ¹ú¼Ê¿ª·¢Ö®Â·¡£Ä¿Ç°º£ºÍÒ©ÎïÒÑÓÐ1¿î²úÆ·£¨¹ÈÃÀÌæÄáƬ£¬ÉÌÆ·Ãû£ºº£Òæ̹®£©»ñÅúÖйúÉÏÊУ¬ÁíÓжà¸öÔÚÑÐÖصã¹ÜÏߵĺòÑ¡Ò©Îï¡£

²Î¿¼ÎÄÏ×£º

  1. Sung, H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3): p. 209–249.
  2. Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.
  3. Shi C, Ning G, Qinglan Z. The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing. Cancer Res. 2024;84(6_Supplement):6499.
  4. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440.
  5. Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–2091.
  6. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328.
  7. ¹úÁ¢¤¬¤óÑо¿¥»¥ó¥¿©`¤¬¤óÇéˆó¥µ©`¥Ó¥¹¡¸¤¬¤ó½yÓ‹¡¹£¨È«¹ú¤¬¤óµÇåh£©18th June 2024, https://ganjoho.jp/reg_stat/statistics/stat/cancer/12_lung.html
| ·¨ÂÉÉùÃ÷ | ÃâÔðÉùÃ÷ | ÁªÏµÎÒÃÇ | Ò½Ò©´ú±í±¸°¸¹«Ê¾ |
¹Ø×¢ÎÒÃÇ
?2020 ÉϺ£º£ºÍÒ©ÎïÑо¿¿ª·¢¹É·ÝÓÐÏÞ¹«Ë¾
°æȨËùÓÐ »¦ICP±¸12016151ºÅ-1
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿
ÓÑÇéÁ´½Ó£º×ðÁú¿­Ê±(Öйú)ÈËÉú¾ÍÊDz«  ÈËÉú¾ÍÊDz©¡¤(Öйú´ó½) - ¹Ù·½ÍøÕ¾  Z6¡¤×ðÁú¿­Ê±¡¸Öйú¡¹¹Ù·½Íø  ×ðÁú¿­Ê±ÈËÉú¾ÍÊDz©z6com¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾  AG¡¤×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!  ÈËÉú¾ÍÊDz«¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾  ×ðÁú¿­Ê±¡¸ÖйúÇø¡¹ÈËÉú¾ÍÊDz«!  ÈËÉú¾ÍÊDz©-×ðÁú¿­Ê±Öйú¹ÙÍø